Mursla Bio publishes peer-reviewed study in the Journal of Extracellular Vesicles, validating its tissue-specific extracellular vesicle (TS-EV) platform for liquid biopsy. This study validates our platform for a new class of liquid biopsy: the multiomic disease biology of living cells in a chosen tissue, read from blood, starting with the liver. Our findings demonstrate the powerful advantages of isolating hepatocyte-derived EVs (h-EVs) over conventional bulk EV approaches: 🔬 A different proteome, not merely a deeper one: bulk EV isolates were dominated by abundant blood-secreted proteins, while h-EVs recovered the intracellular and membrane proteome of hepatocytes, and still identified 57% more proteins with higher reproducibility. 🔬 Disease signatures absent from bulk EVs: 86 liver disease-associated proteins in h-EVs versus 4 in bulk; the proteins unique to HCC h-EVs formed a coherent interaction network, while those unique to bulk EVs formed none. 🔬 Reduced miRNA diversity, richer disease association: h-EVs retained fewer microRNAs, yet only these mapped to HCC-relevant signalling pathways; bulk EV miRNAs reflected generalised inflammation. These findings strengthen the scientific foundation of EvoLiver™, our FDA Breakthrough Device-designated blood test for liver cancer surveillance, and our precision medicine partnerships with pharmaceutical companies. And the potential extends far beyond the liver. With further tissue-specific panels in development, our platform could unlock new opportunities in disease surveillance, molecular residual disease detection and precision medicine, from patient stratification to companion diagnostics. 🔗 Read the press release here: mursla.com/mursla-bio-publis… 🔗 Read the publication here: isevjournals.onlinelibrary.w… #MurslaBio #LiquidBiopsy #ExtracellularVesicles #PrecisionMedicine #LiverCancer

Mursla Bio has been shortlisted for Best Emerging Biotech Company of the Year at the BioUK Awards 2026 🎉 BioUK (formerly @OBN_UK ) brings together one of the UK’s most established life sciences networks, connecting more than 530 organisations across biotech, pharma, investment and the wider ecosystem. The award is sponsored by @thermofisher and judged by a jury of leaders from @EliLillyandCo, @CoEisai, @IpsenUSA, @RosFrankInst and other organisations across the life sciences sector. This national stage award follows our recent success at the Cambridge Independent Science & Technology Awards, where Mursla Bio was Highly Commended for MedTech Company of the Year. This comes at an exciting time for Mursla Bio. Over the past year, we have continued to advance EvoLiver™, our blood based test for liver cancer surveillance in high risk patients, following FDA Breakthrough Device Designation. At the same time, we have been building new biopharma partnerships and expanding the application of our tissue specific extracellular vesicle (TS-EV) platform in precision medicine. It reflects the dedication of our team as we continue to build the next phase of Mursla Bio. Congratulations to all the finalists, and we look forward to the BioUK Awards in October. #BioUKAwards #Biotech #LifeSciences #PrecisionMedicine #MurslaB

🎉 We are proud to announce that Mursla Bio is partnering with a leading global pharmaceutical company to advance its drug for metabolic liver disease. For more information, check out our press release here: lnkd.in/eQEGCfRv #PrecisionMedicine #MASH #Diagnostics #EVScience #BigPharma

✨ We are pleased that Mursla Bio’s core technology was recently featured on @RevvityInc (NYSE: RVTY) website, highlighting its unique precision diagnostic capabilities. The article discusses how Mursla’s approach to isolating organ-specific extracellular vesicles (EVs) from plasma helps overcome a critical challenge in EV and microRNA research. Notably: - In blood, almost all EVs originate from hematopoietic cells, drowning out signals from solid organs. - Following the enrichment for hepatocyte-derived EVs by Mursla's technology, small RNA-seq libraries revealed microRNA species tightly linked to liver biology and liver cancer that were invisible in bulk EVs. This is especially timely as microRNA biology was honored with the 2024 Nobel Prize in Medicine, underscoring its power as a key regulator of gene expression and as a relevant biomarker class. Revvity concludes that: - Organ-specific EVs deliver quality and biological resolution, unlike bulk EVs that only provide quantity. - They enable signals from defined tissues to emerge by analogy to single-cell sequencing, - This sets a new standard for reliable, multi-omic liquid biopsies with true biological interpretability. This capability underpins Mursla Bio’s AI Precision Medicine Platform, which contributed to the development of EvoLiver™, our first product for liver cancer surveillance. Check out the full post here: lnkd.in/eUS4C9_m More details on our NEXPLOR technology can be found in our recent preprint: lnkd.in/dXk54iyS

🧬 Mursla Bio was recently featured in a new article by @statnews , as a leading company that’s supporting the shift to extracellular vesicles (EVs) for early cancer detection. The article explains why many experts are looking beyond DNA-based blood tests. DNA is often present at low levels in early disease and breaks down easily, making detection difficult. EVs offer a compelling alternative. They are released by living cells and carry stable, information-rich cargo that reflects their tissue of origin, helping address critical gaps in test sensitivity and specificity. Our first product, EvoLiver™, designed for the early detection of liver cancer, is based on our breakthrough platform that isolates organ specific EVs from blood. Our platform can be extended to support broader applications in AI enabled precision medicine across oncology, cardiometabolic diseases, and neurology. Read the article here: statnews.com//2025/07/29/ear… [paywall]

🧠 Introducing the Mursla Bio AI Precision Medicine Platform Mursla Bio is proud to announce the launch of its AI Precision Medicine Platform, a full-stack solution enabling organ-specific, multi-omic analysis from blood to advance precision diagnostics and patient stratification. Built on Mursla’s patented extracellular vesicle (EV) technology, the platform enables the isolation of tissue-specific EVs from just 2 milliliters of plasma. It delivers structured, biologically labelled multi-omic data from specific tissues that can drive biomarker discovery, predictive model development, and diagnostic translation. The platform has been validated in a newly released pre-print, developed in collaboration with @Evotec International and University College London (@ucl ). The study demonstrates what we believe to be the most comprehensive scientific validation to date of tissue-EV isolation from a specific human tissue (hepatocytes). Platform highlights: • Patented workflows for tissue-specific EV isolation and biomarker capture • Embedded AI pipelines for multi-omic biomarker discovery and predictive modelling • Proprietary assay formats compatible with standard laboratory instruments • Built for regulatory-grade, scalable diagnostic deployment The platform powers Mursla’s lead program, EvoLiver™, an early disease detection test for liver cancer surveillance in high-risk patients. EvoLiver has received FDA Breakthrough Device Designation. We are now opening access to the platform for strategic collaborations in oncology, cardiometabolic, pulmonary, and neurological diseases. Read the pre-print: biorxiv.org/content/10.1101/… Read the press release: mursla.com/mursla-bio-introd… For partnering enquiries, contact us at: [email protected] #PrecisionMedicine #ArtificialIntelligence #LiquidBiopsy #Diagnostics #EVScience #Biomarkers #MurslaBio #TissueSpecific #MultiOmics #NonInvasive

Last week our FDA Breakthrough Device Designation announcement was the most-read article on @GenomeWeb and @360DxNews – two of the most respected publications in the genomics and diagnostics space. This recognition reflects the growing momentum around our mission to change the way we detect liver cancer and improve patient outcomes. Our CEO, Pierre Arsène spoke to the editors about what this FDA milestone means for Mursla Bio, how we are using organ-specific EVs and multi-omics to shape the future of diagnostics and why our novel blood test EvoLiverTM could transform liver cancer surveillance for high risk individuals. A big thank you to GenomeWeb and 360Dx for spotlighting our work – and to everyone who’s been following our journey. Read the full articles here (paywall): genomeweb.com/cancer/mursla-… 360dx.com/cancer/mursla-bio-… #FDA #BreakthroughDeviceDesignation #LiverCancer #Diagnostics #GenomeWeb #360Dx #MurslaBio

We are proud to announce that EvoLiver™, Mursla Bio’s flagship test for liver cancer surveillance, has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA). The FDA awards Breakthrough Device Designation to a select number of medical devices that offer a more effective diagnosis of life-threatening diseases and represent a significant advancement over existing solutions. The Designation will support priority review, early feedback and more frequent FDA interactions to obtain FDA approved status for EvoLiver™, broadening its market reach and expediting commercial adoption. This follows the announcement of our latest clinical results at AASLD Liver Meeting in San Diego, CA in which EvoLiver™ demonstrated 86% early-stage sensitivity at 88% specificity for liver cancer surveillance among cirrhotic, high-risk patients with diverse etiologies. We are currently progressing towards the launch of EvoLiver™ as a Laboratory Developed Test (LDT), while also advancing our plans for FDA approval via the PMA pathway, which will enable broader clinical adoption and scale-up. Check out our press release here: mursla.com/mursla-fda-receiv… #FDA #BreakthroughDeviceDesignation #MurslaBio #EvoLiver #Diagnostics #EVscience #DynamicBiopsy #LiquidBiopsy

We are delighted to welcome Dr Raquel Sanches-Kuiper as Head of Research & Development at Mursla Bio. Raquel brings over 20 years of leadership experience in diagnostics, genomics and assay development, having most recently served as VP Science & Applications at Evonetix. There, she led multi-disciplinary teams across science and engineering, co-invented multiple patents, and played a key role in securing Series A and B funding. Earlier in her career at Solexa (later acquired by Illumina), Raquel helped establish the core molecular biology function and co-invented DNA polymerase technologies that were foundational to the company’s next-generation sequencing platform. Raquel’s expertise in frontier omics research, technology transfer and commercial readiness will be instrumental as we advance towards the scale-up of our Dynamic Biopsy platform to support the clinical implementation of our flagship product, EvoLiverTM as well as developing our product pipeline. Her arrival marks another important step in our journey to transform clinical diagnostics through organ-specific extracellular vesicles. #MurslaBio #ExtracellularVesicles #EVScience #Innovation #MultiOmics #DynamicBiopsy #LiquidBiopsy

🎉 We are thrilled to share that Mursla Bio has been shortlisted for TWO awards at the 2025 Cambridge Independent (@CambridgeIndy) Science and Technology Awards – The Award for Innovation and MedTech Company of the Year! Being recognised in Cambridge—one of the most vibrant and competitive biotech ecosystems in Europe and globally—is especially meaningful, and sets us on the right path globally as we prepare for our next phase of growth. This recognition is a fantastic endorsement of our vision to transform liver cancer surveillance through EvoLiver™, our Dynamic Biopsy-based blood test powered by organ-specific hepatocyte extracellular vesicles. Check out the full list of finalists: cambridgeindependent.co.uk/b… #MurslaBio #CambridgeIndependent #ExtracellularVesicles #EVScience #MedTech #Innovation #LiquidBiopsy

🚨 EvoLiver™: Setting a New Standard in Liver Cancer Surveillance 🚨 At the AASLD Liver Meeting 2024, we unveiled exciting results from our multi-centre MEV01 study. EvoLiver™, our dynamic biopsy-based blood test, achieved 86% early-stage sensitivity and 88% specificity, surpassing current techniques like ultrasound and AFP. By isolating organ-specific hepatocyte extracellular vesicles (h-EVs) and analysing a novel multi-omics biomarker signature, EvoLiver™ provides precise, non-invasive detection of hepatocellular carcinoma (HCC) among high-risk cirrhotic patients. This scalable test addresses the growing need for earlier, more reliable liver cancer detection, transforming surveillance outcomes while enhancing patient adherence. We are proud to lead this paradigm shift in liver cancer care and thank our academic collaborators and team for their efforts. Next steps include publishing results in 2025, US LDT rollout, and securing FDA approval. More details here: mursla.com Together, we are redefining cancer surveillance. 🌎 #Innovation #DynamicBiopsy #LiverCancer #AASLD2024 #TLMdX

Our Founder & CEO Pierre Arsène spoke with the influential lifescience trade publication The Medicine Maker as part of the prediction’s series, “The Multifaceted Future of Pharma”. For the second piece in the series, Pierre discusses the upcoming clinical translation of extracellular vesicle (EV) science into highly innovative products that could benefit millions of patients in the future. Pierre comments: “Looking ahead, as technological innovations converge, EVs are well positioned to become one of the key biotech disruptors in the next 10 years.” Read the article: shorturl.at/AToK3 (free subscription required to access it)